www.linkedin.com/in/robinhaimbach Cell: 484-***-**** ac0rt8@r.postjobfree.com

SCIENTIST RESEARCH CLINICAL TRAINING and DEVELOPMENT

Innovative, passionate, and collaborative in vivo research physiologist and pharmacologist with extensive experience in the development of new capabilities and models to support renal, cardiovascular, CNS, and uterine proliferative disease drug discovery efforts. Environment: pharmaceutical, healthcare, university. Independent scientist in end to end design, execution, and coordination of preclinical hemodynamic and renal function studies in support of project teams for target validation, risk assessment, and compound screening. Strong analytical and data interpretation skills, plus skill with oral presentation and written documents. Collaborative

and strong team member.

PROFESSIONAL EXPERIENCE

Merck and Co., Inc.

Senior Scientist, Kenilworth Chronic Kidney Disease/Fibrosis, Cardiometabolic 2013 - 2017

Executed timely target validation study in an acute nephropathy mouse model and generated data driving a Go decision.

Introduced and utilized a novel fluorescent transcutaneous glomerular filtration rate measurement in rats to enable better evaluation of the reno-protective potential of novel agents.

Developed and performed chronic diabetic nephropathy rat renal function/metabolic studies to validate targets.

Scientist, Rahway Cardiorenal Group, In Vivo Pharmacology 2011 - 2013

Established the conscious rat renal clearance model (gold standard method).

Expanded capability of renal clearance by validating sinistrin plasma disappearance curve.

Performed rat BP telemetry/diuretic studies for efficacy and de-risking screens.

Animal Tech III, West Point Vaccine Basic Research 2010 – 2011

Performed a murine sepsis model for evaluation of potential vaccine components.

Supported development and problem-solved a rat model of bio-film growth.

Conducted qPCR assays.

GlaxoSmithKline Pharmaceuticals, King of Prussia, PA

In vivo Biologist, COPD Biology, Respiratory CEDD 2009 – 2009

Collaborated with remote medicinal chemists to execute lead optimization screens in rodent acute challenge lung models

Developed an in vivo neutropenia assessment assay.

Senior Scientist, Department of Urogenital Biology 2003 - 2008

Performed and managed the in vivo portion of early preclinical drug discovery efforts to enable advancement of clinical lead and backup compounds.

Founding scientist in new women’s health initiative and progressed compounds to the clinic for a selective progesterone receptor modulator in less than 5 years.

Developed a novel magnetic resonance imaging based methodology of rat endometriosis resulting in advancing compounds to the clinic in record breaking time.

Senior Scientist, Department of Investigational and Product Support 2001 - 2003

Established chronic cardiac output rat model with on-line data acquisition (DSI and Ponemah) to support clinical development team.

Performed and improved orthostatic hypotension studies in the anesthetized rat that resolved conflicting interspecies data.

Proposed and performed the addition of blood pressure telemetry to a rat model of diet-induced end organ damage that led to target validation.

Senior Scientist, Laboratory Animal Science Research Group 1999-2001

Demonstrated the first ever progressive stroke in the rat using MRI, mimicking human clinical data. Trained colleagues for MCAO to evaluate in-house drug candidates.

Performed vascular and telemetry surgeries for development and research scientists.

Senior Scientist in Department of Renal Pharmacology 1983-1999

Conducted conscious chronically instrumented rat renal function models to provide major decisive data of carvedilol over labetalol, resulting in the in-licensing of Coreg.

Performed and enhanced conscious chronically instrumented rat renal function and cardiovascular models from surgery to data analysis.

Trained many scientists in microsurgical techniques and rat renal function methods.

Managed the Renal Pharmacology analytical laboratory and Renal Clearance Laboratory.

Explored and established on-line data collection and telemetry for renal pharmacology.

Increased productivity of the analytical lab by improving sample tracking, handling, and throughput.

EXPERIENCE and SKILLS

In vivo capabilities

Identified and implemented innovative capabilities to determine renal function

Blood pressure (telemetry, catheter/transducer), glomerular filtration rate (gold standard and transcutaneous FITC-sinistrin), flow probes (cardiac output, renal blood flow), novel estrous cycle tracking

Metabolic cage studies for intake and renal function (rat and mouse)

Preclinical model development and pharmacology

Designed, developed, performed and coordinated diabetic nephropathy, conscious rat renal clearance, and autologous uterine implant rat studies

Surgical (microsurgery)

Rat – catheters (jugular, carotid, gastric, duodenal, bladder, femoral artery/vein), telemetry (femoral and abdominal aorta), flow probes (ascending/descending aorta (cardiac output), renal artery, middle cerebral artery occlusion (MCAO), uterine homologous transplant, minipump (sc, ip, iv)

Mouse – ovariectomy, minipump

Guinea pig – uterine patch homologous transplant

In vitro skills

ELISA, Mesoscale, LC/MS sample prep, qPCR, HPLC, RIA, cell culture, RNA extraction, Western blot, SPA assay, Elispot, auto analyzer, spectrophotometry, fluorometry

AWARDS

2016 Award for Excellence – collaborated on end of year study during very challenging times for evaluation of target engagement biomarkers for PDE 9 inhibition.

2015 Award for Excellence - executed critical target validation studies under tight timelines that supported the decision for continued effort of the target.

2014 Merck Special Achievement Award from Cardiometabolic Disease for developing chronic kidney disease in vivo capabilities and testing molecular entities in a chronic diabetic nephropathy rat model plus innovative work on inutest clearance.

2005 Cardiovascular and Urogenital Center of Excellence in Drug Discovery Exceptional Science Award for development of a rat endometriosis model utilizing non-invasive magnetic resonance imaging for assessment of compound effects.

2005 GSK Animal Welfare Award for reducing animal number and assay refinement.

2000 Impact Award for Surgical Research Specialist certification.

PROFESSIONAL CERTIFICATIONS

Surgical Research Specialist Certification (SRS) (2000-2013)

Registered by American Society of Clinical Pathologists - MT(ASCP)

EDUCATION

Delaware Valley Community College – Accelerated PA teaching certificate course – 2010

Lehigh University remote education – Molecular Biology graduate course

B.S., Medical Technology, Arcadia University, Glenside, PA

PUBLICATIONS ( Haimbach / DeWolf )

1.Pancari G, Fan H, Smith S, Joshi A, Haimbach R, Clark D, Li Y, Hua J, McKelvey T, Ou Y, Drummond J, Cope L, Montgomery D, McNeely T. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Frontiers in Cellular and Infection Microbiology. 2012 Mar 20;2:36. doi: 10.3389/fcimb.2012.00036. eCollection 2012.

2.Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Experimental Neurology 2008 Jul;212(1):53-62. Epub 2008 Mar.

3.Lenhard SC, Haimbach RE, Sulpizio AC, Brooks DP, Bray JD, Jucker BM. Non-Invasive Assessment of Ectopic Uterine Tissue Development in Rat Using Magnetic Resonance Imaging. Fertility and Sterility 2007 Oct;88(4Suppl):1058-64.

4.Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN. Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003 Dec;307(3):932-8.

5.Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein DH, Smith SA, Cobitz AR, Sarkar SK. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism. 2003 Feb;52(2):218-25.

6.Jucker BM, Schaeffer TR, Haimbach RE, McIntosh TS, Chun D, Mayer M, Ohlstein DH, Davis HM, Smith SA, Cobitz AR, Sarkar SK. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes. 2002 Jul;51(7):2066-73.

7.Parsons, A., Irving, E., Legos, J., Lenhard, S., Chandra, S., Schaeffer, T., Haimbach, R., White, R., Hunter,A.J., Barone, F., Acute stroke therapy: Translating preclinical neuroprotection to therapeutic reality. Cur. Op. Invest. Drugs 1(4):452-***-****.

8.Laping, N.J., Olson, B.A., DeWolf R.E., Albrightson, C.R., Fredrickson, T., King, C., Chirivella, M., Ziyadeh, F.N., Nambi, P. Activation of glomerular mesangial cells by hepatocyte growth factor through tyrosine kinase and protein kinase C. Biochemical Pharmacology. 55(2):227-34, 1998 Jan 15.

9.Gellai M., Schreiner, GF., Ruffolo, RR Jr., Fletcher T., DeWolf, R., Brooks, DP. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. Journal of Pharmacology & Experimental Therapeutics. 286(3):1191-6, 1998 Sep.

10.Gellai, M., DeWolf, R., Fletcher, T., and Nambi, P. Contribution of endogenous endothelin to the maintenance of vascular tone: role of nitric oxide. Pharmacology 55:299-308, 1997.

11.Gellai, M., DeWolf, R., Pullen, M., and Nambi, P. Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 46:1287-1294, 1994.

12.Gellai, M., Jugus, M., Fletcher, T., DeWolf, R., and Nambi, P. Reversal of postischemic ARF with a selective ETA receptor antagonist in the rat. J. Clin. Invest. 93:900-906, 1994.

13.Gellai, M., DeWolf, R.E., and Ruffolo, R.R., Jr. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology 41:200-206, 1990.

14.Gellai, M., DeWolf, R.E., and Ruffolo, R.R., Jr. Effect of dopamine b-hydroxylase inhibition on systemic hemodynamics in conscious, spontaneously hypertensive rats. Pharmacology 41:82-90, 1990.

15.Gellai, M., DeWolf, R.E., Kinter, L.B., and Beeuwkes, R., III. The effect of atrial natriuretic factor on blood pressure, heart rate and renal functions in conscious, spontaneously hypertensive rats. Circ. Res. 59:56-62, 1986.

16.Olson, E.B., Jr., DeWolf, R.E., and Rankin, J. Uptake and metabolism of norepinephrine in isolated perfused fetal, newborn and adult rabbit lungs. Life Sci. 32:321-327, 1983.

ABSTRACTS

1.Robin Haimbach, Lijun Ma, Maarten Hoek, Shirly Pinto, Xiaoyan Zhou. Longitudinal Characterization of Glomerular Filtration Rate of the Naïve ZSF1 Rat. American Society of Nephrology, Kidney Week November 2016.

2.J.J. Legos, R.G. Bentley, R.E. Haimbach, M.J. McVey, T.R. Schaeffer, S.C. Lenhard, S.K. Sarkar, E.H. Ohlstein, F.C. Barone, S. Chandra, and A.A. Parsons. Selective ETA Antagonism Enhances Brain Perfusion and Reduces Cortical Injury Following Middle Cerebral Artery Occlusion. Submitted to Brain 2001 International Cerebral Blood Flow and Metabolism in Taipei, Taiwan, June 10-14, 2001.

3.S. C. Lenhard, J. J.Legos, R.E. Haimbach, R.G. Bentley, T. R. Schaeffer, F. C. Barone, E.H. Ohlstein, S. K. Sarkar, A. A. Parsons and S. Chandra. SB 234551 improves cortical collateral perfusion following permanent MCAO in the rat. Submitted to International Society of Magnetic Resonance in Medicine in 2001 Glasgow meeting.

4.S. C. Lenhard, J.J. Legos, T.R. Schaeffer, R.E. Haimbach, E.H. Ohlstein, F.C. Barone, A.A.Parsons, S.K.Sarkar, and S. Chandra. MRI Signature Differences in Animal models of cerebral focal ischemia and their Potential Implications in Evaluating Therapy. Submitted to Experimental Nuclear Magnetic Resonance Conference in Orlando Florida in March 2001.

5.Jeffrey J. Legos, Joseph A. Erhardt, Robin E. Haimbach, Patrick M. Boland, Sudeep Chandra, Stephen Lenhard, Susanta K. Sarkar, Elaine A. Irving, A. Jacqueline Hunter, Eliot Ohlstein, Frank Barone, and Andrew A. Parsons Extracellular Signal Regulating Kinase Phosphorylation and Diffusion Weighted Imaging: Dual Markers of Infarct Progression. Submitted to Stroke 2001 in Fort Lauderdale February 14-16, 2001

6.Jeffrey J. Legos, Stephen C. Lenhard, Robin E. Haimbach, Thomas R. Schaeffer, Ross G. Bentley, Frank, C. Barone, Sudeep Chandra, and Andrew A. Parsons,. Use of MRI Perfusion/Diffusion Signatures to Characterize the Therapeutic Window for a Selective ETA Receptor Antagonist in an Animal Model of Focal Stroke. Submitted to The 53rd Annual Meeting of the American Academy of Neurology, 2001.

7.Gellai, M., DeWolf, R., Fletcher, T., and Nambi, P. Physiological roles of endothelin (ET) receptor subtypes in the rat. Am. Soc. Nephrol., 1995.

8.Gellai, M., DeWolf, R., and Walls, T. ETA receptor subtype and renal function in the rat. FASEB J., 1993.

9.Nambi, P., Pullen, M., DeWolf, R., and Gellai, M. Protein kinase C (PKC) in warm ischemia-induced acute renal failure (ARF). J. Amer. Soc. Nephrol. 2:652, 1991.

10.DeWolf, R., Jugus, M., Uyehara, C.F.T., and Gellai, M. Correction of chronic hyponatremia by an alpha-2 adrenoceptor agonist. Presented at the American Society of Nephrology 22nd Annual Mtg, Dec. 3-6, 1989, Washington, DC.

11.Gellai, M., Uyehara, C. and DeWolf, R. Prevention of hyponatremia by alpha-2 adrenoceptor agonists. FASEB J. 3:A415, 1989.

12.Gellai, M. and DeWolf, R. Atrial peptide inhibits reflex compensation to hemorrhage. Fed. Proc. 46:798, 1987.

Contact this candidate